secwatch.observer — SEC 8-K summary
======================================

Issuer:     DMK PHARMACEUTICALS Corp (—)
CIK:        0000887247
Form:       8-K
Filed at:   2022-12-30T23:59:59+00:00
Accession:  0001387131-22-012903
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 3.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adamis receives Nasdaq delisting notice for bid-price non-compliance; plans appeal
--------------------------------------------------------------------------------

- Nasdaq Staff issued delisting determination on Dec 28, 2022, for failure to meet minimum bid price under Rule 5550(a)(2).
- Company had two 180-day grace periods through Dec 27, 2022, but did not regain compliance.
- Adamis will timely request a hearing before the Nasdaq Hearings Panel, which stays delisting pending decision.
- If delisted, shares would be eligible to trade on the OTC Markets platform.
- No assurance that the Panel will grant continued listing or additional compliance extension.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/887247/000138713122012903/0001387131-22-012903-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/887247/000138713122012903/admp-8k_122822.htm
  HTML page:      https://secwatch.observer/filing/0001387131-22-012903

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer